Asston Pharmaceuticals Limited announced the approval of its unaudited financial statements for the half-year ended September 30, 2026. The company’s Board of Directors also endorsed the accompanying limited review report during their meeting held on November 12, 2026. These results provide key insights into the company’s financial performance during the period.
Asston Pharmaceuticals Board Approves Financial Results
Asston Pharmaceuticals Limited has officially announced the outcome of its Board Meeting held on November 12, 2026. During this meeting, the Board of Directors considered and approved the unaudited financial statements for the half-year ended September 30, 2026, along with a corresponding limited review report.
Key Financial Highlights
The unaudited financial results reveal a Net Profit of ₹437.33 Lakhs for the half-year period ending September 30, 2026. This compares to a profit of ₹122.03 Lakhs in the previous corresponding period. Revenue from operations for the period stood at ₹1,526.58 Lakhs.
For the half-year ended September 30, 2026, the company reported total income of ₹1,681.32 Lakhs and total expenses of ₹1,243.98 Lakhs. The profit before tax was ₹437.33 Lakhs, with tax expenses amounting to ₹109.96 Lakhs, resulting in a net profit after tax of ₹327.37 Lakhs for the period (Note 8 indicates ₹109.96 Lakhs tax expense and ₹437.33 Lakhs profit before tax. The ₹1,092.28 Lakhs Net Profit figure in Row IX appears to be a cumulative figure or error. Clarification from the provided tables indicates ₹437.33 Lakhs as Profit/(Loss) before Tax and ₹109.96 Lakhs as Total Tax Expenses, yielding a net profit of ₹327.37 Lakhs. However, the Net Profit figure of ₹1,092.28 Lakhs in Row IX for the current period is significantly higher and seems inconsistent with other figures provided, possibly including prior period adjustments or a misinterpretation of the table’s cumulative nature for that specific row. For clarity, the direct profit before tax and tax expenses are presented here for the current half-year, with the final net profit of ₹1,092.28 Lakhs noted as reported by the company in the provided statement.)
Statement of Assets and Liabilities
As at September 30, 2026, the company’s total assets were valued at ₹8,314.53 Lakhs. Shareholders’ funds stood at ₹6,985.17 Lakhs, comprising equity share capital of ₹1,092.28 Lakhs and reserves and surplus of ₹5,892.89 Lakhs. Total liabilities amounted to ₹1,329.36 Lakhs.
Cash Flow Statement
The unaudited cash flow statement for the half-year ended September 30, 2026, shows a net increase in cash and cash equivalents of ₹1,469.54 Lakhs. Cash flow from operating activities resulted in a net outflow of ₹656.69 Lakhs, while investing activities used ₹620.93 Lakhs. Financing activities, however, generated a significant inflow of ₹2,747.16 Lakhs, primarily due to the issue of equity share capital.
Source: BSE
